| Drug Name | Dotarem (Gadoterate) |
|---|---|
| Drug Class |
Central nervous system stimulant
|
| Risk minimization type |
Direct Healthcare Professional Communication DHPC
|
| Specialty (Theraputic area) |
Neurology
|
| Risk |
risk of brain deposits of gadolinium-based products associated with repeated use in magnetic resonance imaging (MRI) |
| Dear Healthcare provider letter DHPC |
|